Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy
Information source: Northwestern University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Head and Neck Cancer
Intervention: Pulmozyme (Drug); Placebo (Drug); Radiation Therapy (Radiation)
Phase: Phase 0
Status: Active, not recruiting
Sponsored by: Northwestern University Official(s) and/or principal investigator(s): Bharat B. Mittal, MD, Study Chair, Affiliation: Robert H. Lurie Cancer Center
Summary
RATIONALE: Nebulized dornase alfa inhalation solution may decrease the thickness of saliva
in the mouth and improve quality of life in patients undergoing radiation therapy and
chemotherapy for head and neck cancer. It is not yet known whether dornase alfa inhalation
solution is more effective than a placebo in lessening the discomfort of treatment in these
patients.
PURPOSE: This randomized clinical trial is studying how well dornase alfa inhalation
solution works compared with a placebo in treating patients with stage III or stage IV head
and neck cancer undergoing radiation therapy and chemotherapy.
Clinical Details
Official title: A Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation and Chemotherapy
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care
Primary outcome: Treatment-related symptoms as assessed daily by the Head and Neck Symptom Inventory Scale (MD Anderson Symptom Inventory)Quality of life as assessed weekly by the Functional Assessment of Cancer Therapy - Head & Neck Neck questionnaire Patient comfort and/or disturbance during radiotherapy treatment as assessed daily by Radiation Treatment Disturbance Disturbance Measures questionnaire
Secondary outcome: Reduction in amount of thick oropharyngeal secretions associated with cancer therapy.Incidence of mucositis, infections, and aspiration pneumonia
Detailed description:
OBJECTIVES:
- To determine if use of nebulized dornase alfa inhalation solution can improve the
overall daily symptom and quality of life as well as reduce treatment discomfort during
radiotherapy and chemotherapy in patients with stage III or IV squamous cell carcinoma
of the head and neck.
- To determine if once daily nebulized dornase alfa inhalation solution given prior to
radiotherapy can reduce thick oropharyngeal secretions associated with curative
radiotherapy and chemotherapy in these patients.
- To determine if reduction in thick oropharyngeal secretions with the use of nebulized
dornase alfa inhalation solution can decrease the incidence of mucositis, infections,
and aspiration pneumonia.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive nebulized dornase alfa inhalation solution via oral inhalation
approximately 30 minutes prior to radiation therapy on days 1-5. Treatment continues
for up to 4 weeks (weeks 3-6 of radiation therapy) in the absence of disease
progression or unacceptable toxicity.
- Arm II: Patients receive nebulized placebo via oral inhalation approximately 30 minutes
prior to radiation therapy on days 1-5. Treatment continues for up to 4 weeks as in arm
I.
All patients are assessed for treatment-related symptoms and treatment disturbance daily
during radiation therapy. Patients are assessed for quality of life weekly during radiation
therapy and then monthly during follow-up for 3 months. Clinical symptoms (i. e., mucositis,
bacterial and fungal infections, and aspiration pneumonia) are also assessed weekly during
radiation therapy.
Sputum samples are collected prior to initiating radiation therapy (at baseline) and
periodically during week 3 of radiation treatment and evaluated for salivary DNA levels.
After completion of study therapy, patients are followed monthly for 3 months and then every
3-4 months for a minimum of 2 years.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity,
nasopharynx, oropharynx, hypopharynx, or larynx
- Stage III or IV disease
- Confirmation from primary site and/or lymph nodes
- Patients with a history of head and neck cancer allowed provided they have not
received prior radiotherapy
- Prior localized radiotherapy for skin cancer arising in the head and neck region
is allowed
- Planning to receive radiation therapy and chemotherapy to the head and neck regions
with a minimum expected radiation dose of 60 Gy over 6 weeks
- Chemotherapy may include but is not limited to, cisplatin or carboplatin,
fluorouracil, hydroxyurea, docetaxel, and/or cetuximab
- Induction chemotherapy allowed
PATIENT CHARACTERISTICS:
- Karnofsky performance status 50-100%
- No prior allergic reaction or known sensitivity to dornase alfa inhalation solution
- No significant active infection or other severe complicating medical illness
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No concurrent amifostine
- No mouth wash 1 hour before or after dornase alfa inhalation solution administration
Locations and Contacts
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois 60611-3013, United States
Additional Information
Starting date: February 2008
Last updated: June 25, 2013
|